Interactive Transcript
0:01
The following is a 65-year-old
0:03
gentleman with cirrhosis who's being
0:04
screened for hepatocellular carcinoma.
0:07
A few liver lesions, but we're going
0:09
to focus on this one over here.
0:10
So here we have a T2-weighted
0:12
image with fat saturation.
0:14
And this is a T1-weighted image with
0:16
fat saturation without contrast.
0:20
And this is the lesion in question,
0:21
better seen on this sequence over here.
0:23
On the T1-weighted images, it's relatively hyper-
0:26
intense when compared to the liver parenchyma.
0:28
On the T2 images, it's very difficult
0:30
to see. It's probably iso-intense
0:34
with respect to the liver parenchyma.
0:36
And so something like this, you know,
0:38
could be considered one of these
0:39
cirrhotic nodules given its appearance,
0:42
possibly this is a dysplastic nodule.
0:45
The next thing to look for in any of
0:46
these nodules is to see if there's
0:48
any internal enhancement within it.
0:50
So here we have a T1-weighted sequence
0:52
with fat saturation, with contrast.
0:55
This is in the arterial phase.
0:56
This one over here is in the portal
0:58
venous phase, a little bit later.
1:00
What I'm actually showing you here are
1:02
subtracted images, and the reason we use
1:04
subtracted images is because this lesion
1:06
has hyperintense T1 content to begin with.
1:10
So you want to make sure you remove that
1:12
prior to looking at the post-contrast
1:13
images, hence the use of subtracted images.
1:16
We can find the lesion again, right
1:18
over here and right over here.
1:20
In the medial left hepatic lobe, and it
1:22
doesn't demonstrate any internal enhancement.
1:24
So, we have a lesion, it's T1 hyperintense,
1:27
T2 isointense, no enhancement.
1:30
It would not be unreasonable to
1:32
describe this as a dysplastic nodule.
1:34
Now, as it has been mentioned, these
1:36
dysplastic nodules can undergo various degrees
1:38
of differentiation from low grade to high
1:40
grade, and once you start getting to the
1:42
high grade, many people consider them
1:45
as precursor lesions to developing frank
1:47
malignancy, which is hepatocellular carcinoma.
1:50
And the key then when evaluating serial
1:53
studies and looking at these nodules is
1:55
to really see, does the imaging appearance
1:57
change on subsequent studies as the T2
2:00
appearance changes, the T1 appearance changes?
2:02
Is there any enhancement associated with this?
2:05
So if we fast-forward imaging studies on this
2:08
patient to about a year after that initial
2:10
imaging study, we can relook at this nodule
2:13
in the medial left hepatic lobe.
2:14
And on the T2-weighted image
2:16
with fat saturation, we can see
2:18
that its appearance has changed.
2:20
Previously, it was isointense with
2:22
respect to the liver parenchyma, but
2:24
now, certainly internally, if you look at
2:25
this portion of it, it is hyperintense.
2:29
If we look at this nodule on the T1-
2:31
weighted sequence with fat saturation,
2:33
before giving contrast, again, the
2:36
nodule's appearance has changed.
2:37
It probably has gotten a little bit
2:39
bigger. But internally, it is hypointense
2:42
with respect to the liver parenchyma,
2:44
whereas previously it was hyperintense or
2:46
brighter than the liver parenchyma itself.
2:48
Finally, we can look at this nodule on
2:50
the T1-weighted fat-saturated image.
2:53
Post-contrast, this one
2:55
is in the arterial phase.
2:57
And internally, not a lot of
2:59
enhancement at this cut over here.
3:01
But if we scroll up and down through this
3:03
lesion, what we find is that there are
3:04
foci of internal enhancement that are new.
3:07
As can be seen along the cephalodermal aspect of
3:11
this lesion, this little nodule of enhancement.
3:13
And so this is sometimes referred to
3:15
as a nodule-within-a-nodule appearance.
3:19
This enhancing nodule within
3:21
a pre-existing liver nodule.
3:24
There's no washout associated
3:25
with this in this particular case.
3:27
So it's an enhancing nodule within
3:30
an otherwise non-enhancing lesion.
3:32
And this is thought to reflect a more high-
3:35
grade or de-differentiated dysplastic nodule
3:38
that may subsequently become
3:40
a hepatocellular carcinoma.
© 2024 Medality. All Rights Reserved.